

Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy

Federico Alberici^{1,2}, Elisa Delbarba², Chiara Manenti², Laura Econimo², Francesca Valerio², Alessandra Pola², Camilla Maffei², Stefano Possenti², Simone Piva^{1,3}, Nicola Latronico^{1,3}, Emanuele Focà^{4,5}, Francesco Castelli^{4,5}, Paola Gaggia², Ezio Movilli², Sergio Bove⁶, Fabio Malberti⁷, Marco Farina⁸, Martina Bracchi⁹, Ester Maria Costantino¹⁰, Nicola Bossini², Mario Gaggiotti² and Francesco Scolari^{1,2}; on behalf of the Brescia Renal COVID Task Force¹¹

¹Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy; ²Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; ³Intensive Care Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; ⁴Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; ⁵Infectious and Tropical Diseases, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; ⁶Nephrology Unit, Montichiari Hospital, ASST Spedali Civili di Brescia, Montichiari, Italy; ⁷Nephrology Unit, ASST Cremona, Cremona, Italy; ⁸Nephrology Unit, ASST Lodi, Lodi, Italy; ⁹Nephrology Unit, ASST Franciacorta, Chiari, Italy; and ¹⁰Nephrology Unit, ASST del Garda, Manerbio, Italy

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease (COVID-19), is a major pandemic challenging health care systems around the world. The optimal management of patients infected with COVID-19 is still unclear, although the consensus is moving toward the need of a biphasic approach. During the first phase of the disease (from onset of the symptoms up to 7–10 days) viral-induced effects are prominent, with the opportunity to institute antiviral therapy. In the second inflammatory phase of the disease, immunosuppressive strategies (for example with glucocorticoids or anticytokine drugs) may be considered. This latter stage is characterized by the development of progressive lung involvement with increasing oxygen requirements and occasionally signs of the hemophagocytic syndrome. The management of the disease in patients with kidney disease is even more challenging, especially in those who are immunosuppressed or with severe comorbidities. Here we present the therapeutic approach used in Brescia (Italy) for managing patients infected with COVID-19 who underwent kidney transplantation and are receiving hemodialysis. Furthermore, we provide some clinical and physiopathological background, as well as preliminary outcome data of our cohort, to better clarify the pathogenesis of the disease and clinical management.

Kidney Int Rep (2020) ■, ■-■; <https://doi.org/10.1016/j.ekir.2020.04.001>

KEY WORDS: COVID-19; dialysis; kidneys; management; patients; SARS-CoV-2; transplant

© 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

We describe our experience with managing patients with kidney disease during the current COVID-19 pandemic in Brescia City in the Lombardy region of Italy, with particular attention to patients

undergoing dialysis and patients with renal transplantation.

The Chinese Center for Disease Control and Prevention recently published the largest COVID-19 case series, which includes 44,672 cases. This study shows an overall mortality rate of 2.3%. Besides age (1.3% mortality in the 50–59 age group, 3.6% in the 60–69 age group, 8.0% in the 70–79 age group, and 14.8% in the ≥80 age group), the main risk factors are the presence of cardiovascular diseases (10.5% mortality), diabetes (7.3% mortality), chronic respiratory diseases (6.3% mortality), high blood pressure (6% mortality), and cancer (5.6% mortality).^{1,2} In the Lombardy

Correspondence: Federico Alberici, University of Brescia - ASST Spedali, Civili, Piazzale Spedali Civili 1, 25125 Brescia, Italy. E-mail: federico.alberici@unibs.it

¹¹Members of the Brescia Renal COVID Task Force are listed in the Appendix.

Received 2 April 2020; accepted 2 April 2020; published online 4 April 2020

region, however, the disease seems to have much higher mortality rates than reported in China, and this led us to investigate factors potentially responsible for this worse outcome.³ The comorbidities associated with increased mortality during COVID-19 are common in patients with chronic kidney disease (CKD) and in patients undergoing renal replacement therapy with hemodialysis. There is a paucity of data on the risk factors and outcome of patients with kidney disease who are positive for COVID-19, including those receiving dialysis or who underwent a kidney transplantation. These groups of patients are unique in view of their immunosuppressed status. Reports from China suggest a less severe course of the disease in patients receiving dialysis, compared with patients who underwent a kidney transplantation, but also compared with patients without kidney disease.

Currently, Brescia and its province are the second largest Italian area affected after Bergamo (5317 cases as of March 23, 2020). A working group consisting of infective disease specialists and intensivists from Lombardy has developed a therapeutic protocol in patients with COVID-19 based on disease severity.⁴ We have adapted this protocol to our patients receiving dialysis and who underwent a kidney transplantation. We also provide some logistics considerations resulting from our direct experience in the management of patient flows during the COVID-19 pandemic, as well as preliminary results of outcome in our population.

Logistic Considerations

Proper logistic planning is crucial in the management of this health emergency. The management of these patients makes it necessary to reconcile infection protocols (e.g., isolation), with needs that are intrinsic to our specialty (e.g., the need to move patients for hemodialysis). Our experience, although still limited, suggests a better outcome in patients who underwent a transplantation directly managed in a dedicated nephrology ward compared with the patients managed in other general COVID areas, and evaluated by the nephrologist only in consultation.

As a referral center, our division provides care to 1200 patients who underwent a transplantation, 400 patients receiving hemodialysis, and 70 patients receiving peritoneal dialysis. Because of the significant size of our patient population, we reorganized our wards to accommodate the surge of patients with COVID-19 with kidney disease. The particular logistics of our institution has allowed us to implement an efficient organizational model that included the creation of a dedicated COVID unit from a female ward.

From February 27–28, 2020, we created a dedicated COVID unit that was dialysis capable and subsequently

Table 1. Number of patients at the peak of the COVID pandemic

1st Floor				
Inpatients with COVID-19 infection receiving hemodialysis	Hemodialysis room for inpatients with COVID-19 infection	Hemodialysis rooms for inpatients who are negative for COVID-19	Dialysis room for inpatients with COVID-19 infection or suspected cases	Inpatients with COVID-19 who received transplantation
17 beds			12 beds	
2nd Floor				
Dialysis			COVID-negative nephrology ward	

COVID, coronavirus disease.

admitted the first COVID-positive patient (who underwent kidney transplantation). On February 28, we adopted surveillance measures for outpatients undergoing hemodialysis, which were applied in a small triage area in the waiting room of the dialysis center: patients' body temperature was checked together with a brief anamnestic evaluation, alcohol-based hand sanitizer was dispensed, and surgical masks were provided. If the clinical suspicion of COVID-19 emerged, the patient was sent to perform specific testing. In case of urgency for dialysis treatment, this was performed in a room intended for suspected cases.

Between March 2 and 4, 2020, we admitted the second and third positive patients to the COVID area. As the number of patients infected with COVID-19 increased, we closed the transplant center and rearranged the ward's central spaces to create hemodialysis rooms, intended partially for patients with SARS-CoV-2 infection and partially for patients who are negative for SARS-CoV-2 (see Table 1).

Patient Flow

Logistical challenges and the physical structure of the building (e.g., identifying a room dedicated for isolated patients awaiting the reverse transcriptase-polymerase chain reaction results, locations for donning and doffing personal protective equipment, as well as for performing hemodialysis outside the usual area), we were forced to reduce the number of overall beds from 36 to 29. Because of patient turnover (intensive care unit transfers, discharges, and deaths), these numbers allowed us to cover our needs in terms of admissions for patients who underwent transplantation and who are receiving dialysis.

Up to March 22, in the nephrology unit of the hospital of Brescia, we have managed 46 patients, following the protocol presented in this article: 20 patients who underwent renal transplantation, 21 patients receiving hemodialysis, and 5 patients affected by CKD or acute kidney injury on CKD. The vast majority of patients (19 of 20 patients who underwent transplantation, 17 of 21 patients receiving hemodialysis, and 4 of 5 of the patients with CKD) received

antiviral therapy and hydroxychloroquine as per our protocol. Dexamethasone and tocilizumab have been used, respectively, in 11 and 6 of the 20 patients who underwent transplantation, in 4 and 1 of the 21 patients receiving hemodialysis, and in 1 and none of the patients with CKD. To date, no patients on immunosuppressive treatment due to primary or secondary glomerulonephritis have been admitted or known to have symptoms imputable to SARS-CoV-2 infection; these patients were advised to respect social distancing rules since the early stages of the coronavirus crisis.

Results

We now provide preliminary outcome data on the patients directly followed in our nephrology unit in Brescia on March 22, 2020; more detailed reports will follow. As of March 22, among our 20 patients who underwent transplantation who were admitted, 5 patients died, 4 were admitted to the intensive care unit, and 3 were discharged after an average of 13 days.

We admitted 21 patients with COVID-19 infection receiving hemodialysis, including 5 patients who died and 4 who were discharged between hospital day 7 and 17 (mean length of hospitalization 12 days). The COVID-19 crisis has imposed rationalization of intensive care unit resources, and as a result, patients receiving hemodialysis who are often elderly and afflicted by numerous comorbidities are often not considered candidates who will benefit from intensive care unit care.

A total of 5 patients with CKD were admitted, of whom 2 have died and the other 2 have been discharged after 6 and 17 days from admission.

Management Considerations

In general terms, optimal disease management is still being debated, and the therapeutic approach still lacks significant evidence. The indication for antiretroviral therapy is uncertain, and to date there are no approved drugs for the treatment of SARS-CoV-2 infection.⁵ Although anecdotal experience can be drawn from the use of antiviral agents on viruses belonging to the same family of Betacoronaviruses (SARS and Middle East respiratory syndrome), the current COVID-19 pandemic provides the opportunity for testing therapies in affected patients. To date, no clear guidelines exist for the management of these patients.⁶

The pharmacological approach to treating SARS-CoV-2 infection can be viewed as a 2-phase approach. The first phase is associated with viral replication and cytopathic effect, and antiviral drugs may be considered (e.g., chloroquine-hydroxychloroquine, lopinavir/ritonavir, darunavir ritonavir, and darunavir/cobicistat). The second phase of the disease begins after 7 to

10 days from the onset of symptoms, and is associated with the risk of death²; this stage is characterized by progressive lung involvement with escalating needs of oxygen supplementation and ventilatory support, which seems to be secondary to hyperinflammatory and cytokine release syndromes. Immunosuppressive and immunomodulatory drugs may be of benefit during this phase.

Chloroquine-Hydroxychloroquine

Investigational evidence seems to support the role of antiviral activity of chloroquine toward the SARS and avian influenza viruses in *in vitro* and animal models.^{7,8} Clinical evidence to support their use remains limited at this time.⁹ Because of similar molecular structure, a well-known immunomodulating effect,¹⁰ and better safety profile, hydroxychloroquine may be considered as an option in this context,¹¹ and of interest its use has been found to be associated with a higher proportion of patients showing a negative reverse transcriptase-polymerase chain reaction from day 3 after its introduction compared with untreated controls in small series.¹²

Lopinavir/Ritonavir, Second-Generation Antiretroviral

Anecdotal evidence seemed to support their possible role in COVID-19; however, a recent analysis failed in showing benefit with lopinavir/ritonavir treatment beyond standard care in hospitalized adult patients with severe COVID-19,¹³ but these results are limited and, in our opinion, not conclusive. For example, baseline characteristics suggest a higher disease severity in the treatment arm (more patients with respiratory rate >24/min, with days from onset to randomization >12 and requiring oxygen) and, interestingly, an associated higher viral load. Despite that, patients treated with lopinavir/ritonavir experienced a higher proportion of clinical improvement on day 14 (45.5% vs. 30.0%), a shorter time to clinical improvement if treated within 12 days from onset (hazard ratio 1.25; 95% confidence interval: 1.77–2.05), and were less likely to die (19.2% vs. 25.0%, not significant). In our opinion, these data support consideration of antiviral therapy in subgroups of patients at high risk.

Darunavir Ritonavir and Darunavir/Cobicistat

These are potential alternatives to lopinavir/ritonavir based on the similar mechanism of action.

Remdesivir

Remdesivir is a nucleotide analogue whose mechanism of action consists of incorporating the drug into newly synthesized RNA chains. It has been suggested that it plays a role in reducing viral load and improving lung function parameters in animal and *in vitro* models,^{14,15} acting at the stage of the post virus entry in the cells.⁷

Azithromycin

A small study performed on patients with COVID-19 infection and treated with hydroxychloroquine demonstrated that combination with azithromycin was associated with a higher probability of showing a negative reverse transcriptase-polymerase chain reaction for the virus from the third day after the beginning of the therapy compared with controls and with those who received hydroxychloroquine alone.¹²

Corticosteroids

The use of corticosteroids would be contraindicated in the first phase of the disease, but may play a role in the second phase, the one characterized by potential rapidly progressive lung involvement and secondary to hyperinflammatory syndrome and cytokine release syndrome. Of note, data suggest a significant impact on the survival curves of patients with COVID-19 infection who have developed acute respiratory distress syndrome.¹⁶

Tocilizumab

In consideration of the central role that interleukin-6, in combination with other proinflammatory cytokines, seems to have in the development of the cytokine release syndrome,¹⁷ tocilizumab could play a role in the management of selected cases in the absence of major contraindications.

Clinical Patient Management and Monitoring

Patients with known COVID-19 infection receive a chest X-ray at baseline and repeated when respiratory deterioration is noted. Even patients who are afebrile may have an abnormal chest X-ray and other clinical signs of the hemophagocytic syndrome. These patients tend to be hypercoagulable, and prophylactic therapy with heparin and low-dose aspirin should be considered. During this phase, treatment with glucocorticoid and the interleukin-6 inhibitor tocilizumab should be considered, especially in patients with rapid clinical deterioration evidenced by escalating oxygen requirements or the need for ventilatory support. We recommend for this subgroup of patients, close monitoring of arterial oxygen levels with repeat arterial blood sampling, of the blood tests including ferritin-coagulation-liver enzymes, and of the chest X-ray.

We have formulated a treatment protocol based on patient characteristics, phase of illness, and disease severity using antivirals, immunomodulators, and immunosuppressive agents. These protocols are based on *in vitro* antiviral effects and empirical observations in other countries and are listed in the [Supplementary Material](#). A recent trial did not show efficacy of lopinavir-ritonavir in severe COVID-19 infection, although with the limitations mentioned previously; of

note, data on the role of such approach on subgroups such as patients receiving hemodialysis and who underwent transplantation are still lacking. Our proposed therapeutic management plan for patients receiving hemodialysis and who underwent transplantation with a SARS-CoV-2 infection can be found in the [Supplementary Appendix S1](#). We also provide further considerations for diagnosis and treatment of these patients in the [Supplementary Appendix S2](#).

APPENDIX**Members of The Brescia Renal COVID Task Force**

Federico Alberici, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia Italy; and Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Elisa Delbarba, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Chiara Manenti, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Laura Econimo, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Francesca Valerio, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Alessandra Pola, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Camilla Maffei, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Stefano Possenti, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Nicole Zambetti, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Margherita Venturini, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Stefania Affatato, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Paola Piarulli, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Mattia Zappa, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Alice Guerini, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Francesca Boni, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Alberto Mucchetti, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Elena Pezzini, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Chiara Saccà, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Marianna Moscato, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Michela Tonoli,

Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Stefano Pasquali, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Fabio Viola, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Simone Piva, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia Italy; and Intensive Care Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Nicola Latronico, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia Italy; and Intensive Care Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Emanuele Focà, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; and Infectious and Tropical Diseases, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Eugenia Quiros-Roldan, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; and Infectious and Tropical Diseases, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Francesco Castelli, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; and Infectious and Tropical Diseases, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Paola Gaggia, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Ezio Movilli, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Sergio Bove, Nephrology Unit, Montichiari Hospital, ASST Spedali Civili di Brescia, Montichiari, Italy; Fabio Malberti, Nephrology Unit, ASST Cremona, Cremona, Italy; Marco Farina, Nephrology Unit, ASST Lodi, Lodi, Italy; Martina Bracchi, Nephrology Unit, ASST Franciacorta, Chiari, Italy; Ester Maria Costantino, Nephrology Unit, ASST del Garda, Manerbio, Italy; Nicola Bossini, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; Mario Gaggiotti, Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy; and Francesco Scolari, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia Italy; and Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy.

DISCLOSURE

All the authors declared no competing interests.

SUPPLEMENTAL MATERIAL

Supplementary File (PDF)

Appendix S1. Proposal for a therapeutic management plan for patients receiving hemodialysis and who underwent transplantation and who have a SARS-CoV-2 infection.

Appendix S2. Further considerations for diagnosis and treatment.

REFERENCES

- Falk RJ, Hogan SL, Muller KE, et al. Treatment of progressive membranous nephropathy. *Ann Intern Med.* 1992;116:438–445.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395:497–506.
- Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response [e-pub ahead of print]. *JAMA.* <https://doi.org/10.1001/jama.2020.4031>. Accessed ●●●.
- Pelletier G, Fabre M, Attali P, et al. Light chain deposition disease presenting with hepatomegaly: an association with amyloid-like fibrils. *Postgrad Med J.* 1988;64:804–808.
- Wei LQ, Rong ZK, Gui L, Shan RD. CT diagnosis of renal vein thrombosis in nephrotic syndrome. *J Comput Assist Tomogr.* 1991;15:454–457.
- Naicker S, Yang C, Hwang S, et al. The novel Coronavirus 2019 pandemic and kidneys. *Kidney Int*, in press.
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* 2020;30:269–271.
- Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. *Zhonghua Jie He He Hu Xi Za Zhi.* 2020;43:185–188.
- Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 [e-pub ahead of print]. *J Crit Care.* <https://doi.org/10.1016/j.jcrc.2020.03.005>. Accessed ●●●.
- van den Borne BE, Dijkmans BA, de Rooij HH, et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. *J Rheumatol.* 1997;24:55–60.
- Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression [e-pub ahead of print]. *J Antimicrob Chemother.* <https://doi.org/10.1093/jac/dkaa114>. Accessed ●●●.
- Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [e-pub ahead of print]. *Int J Antimicrob Agents.* doi: 10.1016/j.ijantimicag.2020.105949. Accessed ●●●.
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 [e-pub ahead of print]. *N Engl J Med.* <https://doi.org/10.1056/NEJMoa2001282>. Accessed ●●●.
- Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir,

535	ritonavir, and interferon beta against MERS-CoV. <i>Nat Commun.</i> 2020;11:222.	
536		
537	15. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. <i>Proc Natl Acad Sci U S A.</i> 2020;117:6771–6776.	
538		
539	16. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China [e-pub ahead of print]. <i>JAMA Intern Med.</i> https://doi.org/10.1001/jamainternmed.2020.0994 . Accessed ●●●.	
540		
541	17. Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. <i>Biol Blood Marrow Transplant.</i> 2019;25:e123–e127.	
542		
543		
544		
545		
546		
547		
548		
549		
550		
551		
552		
553		
554		
555		
556		
557		
558		
559		
560		
561		
562		
563		
564		
565		
566		
567		
568		
569		
570		
571		
572		
573		
574		
575		
576		
577		
578		
579		
580		
581		
582		
583		
584		
585		
586		
587		
588		
	18. Zhang W, Bai M, Yu Y, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. <i>Crit Care.</i> 2019;23:22.	589
		590
		591
		592
	19. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases [e-pub ahead of print]. <i>Radiology.</i> https://doi.org/10.1148/radiol.2020200642 . Accessed ●●●.	593
		594
		595
		596
	20. Cantalupi V, Marengo M, Quercia A, et al. Removal of large-middle molecules, inhibition of neutrophil activation and modulation of inflammation-related endothelial dysfunction during expanded hemodialysis (HDx). <i>Nephrol Dial Transplant.</i> 2019;34(Suppl 1):gfz096.FO048.	597
		598
		599
		600
		601
		602
		603
		604
		605
		606
		607
		608
		609
		610
		611
		612
		613
		614
		615
		616
		617
		618
		619
		620
		621
		622
		623
		624
		625
		626
		627
		628
		629
		630
		631
		632
		633
		634
		635
		636
		637
		638
		639
		640
		641
		642